Article Title: Park TW, Saitz R, Ganoczy D, Ilgen MA, Bohnert AS. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study. BMJ. 2015 Jun 10;350:h2698.
tronic medical records of VHA patients, prescription data obtained from VHA's Pharmacy Benefits Management Services (PBM; to confirm fulfillment of prescriptions) and the National Death Index (NDI; to establish cause of death). Benzodiazepine and opioid doses were standardized to diazepam and morphine, respectively. Baseline demographic characteristics were compared with χ 2 tests. Death rates were calculated based on history of benzodiazepine use, and the type, dose, and scheduled use of the benzodiazepine. Hazard ratios (HRs) were calculated using Cox proportional hazards model and adjusted for all covariants (e.g., opioid dose).
Results: During the study period, 2400 deaths from drug overdose (cases) were identified, and 420,386 subjects (a 5 % random sample of the entire population) served as controls. Among the cases, 1185 (49 %) died during a period when they were prescribed an opioid and benzodiazepine. Among the controls, 112,069 (27 %) were prescribed a benzodiazepine at least once while receiving an opioid. Subjects also receiving a benzodiazepine were more likely to be women (33 % compared to 26 % men), middle aged, white, and living in wealthier zip codes. Additional predictors for a concurrent benzodiazepine prescription included a recent admission for mental health or substance abuse disorder or a diagnosis of psychiatric or substance abuse disorder.
Unadjusted rates of death from drug overdose were associated with higher doses of opioids or benzodiazepines and an active prescription for a benzodiazepine.
After adjusting for covariants and compared to periods of time when no benzodiazepine was prescribed, the active use of a benzodiazepine (HR 3.96; ) and past benzodiazepine prescription (HR 2.33; 95 % CI 2.05-2.64) were both associated with increased death from a drug overdose.
Conclusion: Current benzodiazepine use was associated with increased risk of death from drug overdose in US veterans receiving opioid analgesics. This association was more pronounced with increased doses of either drug.
Critique: The generalizability of this study is limited by the population being mostly male veterans, and only those prescriptions filled through the VHA were included. Diagnoses for which these prescriptions were used are unknown; it is possible that deaths were falsely attributed to concurrent prescription instead of mental illness. However, medical diagnoses were adjusted for in the analysis. Overall, this study did obtain information from multiple sources and adjusted for confounding factors.
Implication for Toxicologists: This article should prompt toxicologists and poison centers to perform detailed medical reconciliation to identify and possibly prevent bad outcomes. We should take a more active role in discharge planning, instead of focusing only on the acute management of benzodiazepine and opioid toxicity.
Article Title: Orliaguet G, Hamza J, Couloigner V, Denoyelle F, Loriot MA, Broly F, Garabedian EN. BA Case of Respiratory Depression in a Child With Ultrarapid CYP2D6 Metabolism After Tramadol.^Pediatrics 2015. 135.3: e753-e755.
Background: Respiratory depression and fatalities in children given codeine for pain have led to restriction in its use. Codeine is metabolized to morphine via CYP2D6, and patients with polymorphisms (increased 2D6 activity, Bultra-rapid metabolizers^) can rapidly produce higher morphine concentrations and experience adverse events. Tramadol has been proposed as a substitute, based on an assumed safer profile, but it too is extensively metabolized by 2D6 to a more active metabolite, O-desmethyltramadol (M1). However, there have been no previous reports of significant respiratory depression in children treated with tramadol.
Research Question: The authors report a novel case of respiratory depression in a child receiving tramadol.
Case: A 5-and-a-half year-old boy had an uncomplicated, outpatient tonsillectomy under general anesthesia and was discharged home that same day. Prior to sleep that evening, he was given a 1-mg/kg dose of tramadol. The next morning he was found lethargic and taken back to the hospital. Upon arrival his GCS was 8 with pinpoint pupils. He had minimal respiratory effort with periods of apnea; oxygen saturation was 48 % and an arterial blood gas revealed the following: pH 7.06, PCO 2 94, PO 2 60. He responded to naloxone (0.5 mg×3) and noninvasive ventilation. Urinary tramadol concentration was elevated, as were the metabolites M1 and N-desmethyltramadol. The low ratio of (tramadol)/(M1) was consistent with CYP2D6 ultra-rapid metabolism, which was confirmed by patient genotyping.
Conclusion: Tramadol use may be associated with increased risk of respiratory depression in children with ultrarapid CYP2D6 metabolism.
Critique: This patient had a history of OSA, which may have placed him at increased risk for respiratory depression, both as a complication of surgery and due to opiate use.
Implication for Toxicologists: Toxicologists should be away of potential adverse effects (CNS and respiratory depression) following the use of tramadol in ultra-rapid metabolizers, particularly children. As patient advocates and frequent members of pharmacy and therapeutics committees, toxicologists must be aware of this potential risk following therapeutic dosing.
Article Title: Hernandez I, Baik SH, Piñera A, Zhang Y. Risk of Bleeding With Dabigatran in Atrial Fibrillation. JAMA Internal Medicine 2015 Jan. 175(1): 18-24.
Background: The Food and Drug Administration (FDA) approved dabigatran for the prevention of stroke and embolism in patients with atrial fibrillation (AF) in 2010 based on the results of the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. This study found dabigatran to be superior to warfarin in the prevention of stroke. Dabigatran was associated with higher risk of gastrointestinal bleeding (GIB), but a lower rate of intracranial hemorrhage (ICH) compared to warfarin. However, within months of FDA approval, cases of severe dabigatran-related bleeding were reported. Subsequent studies have presented conflicting evidence about whether or not the risks of GIB and ICH were higher with dabigatran compared to warfarin.
Research Question: Do patients with AF who take dabigatran have higher risks of GIB and ICH than AF patients taking warfarin?
Methods: This was a retrospective cohort study using Medicare beneficiary data from 2010 to 2011. A random sample of 5 % of all Medicare patients was used. Subjects diagnosed with AF, between October 1, 2010 and October 31, 2011, and then started either dabigatran or warfarin treatment within 2 months of their AF diagnosis were identified. Subjects were followed from their first prescription until one of the study's end points: discontinuation of initial therapy, change in anticoagulant, death, or December 31, 2011. The final study sample included 1302 dabigatran users and 8102 warfarin users. Nine types of bleeding were identified by ICD-9 codes and categorized into either major bleeding (ICH, hemoperitoneum, and emergency department or inpatient stays for GIB, hematuria or hemorrhage NOS) and minor bleeding (epistaxis, hemoptysis, vaginal hemorrhage, hemarthrosis, and outpatient visits for GIB, hematuria, or hemorrhage NOS).
Time to bleeding was defined as the time interval between the day of receiving the anticoagulant prescription and day of the bleeding event. Time to first bleeding event and time to first major bleeding event were both recorded. Propensity score weighing (adjusted for patient demographics and clinical characteristics) was used in a Cox proportional hazards regression model to examine the risk (hazard ratios; HRs), of bleeding by severity and site. The authors further examined the incidence of bleeding in four high-risk subgroups: patients 75 years and older, African Americans, those with chronic kidney disease (CKD), and those with seven or more comorbidities in addition to AF.
Results: Dabigatran was associated with a statistically significantly higher risk of major bleeding and all bleeding relative to warfarin. The adjusted incidence of major bleeding was 9.0 % (95 % CI 7.8-10.2) for the dabigatran group and 5.9 % (95 % CI 5.1-6.6) for the warfarin group. When compared to warfarin, dabigatran's HRs were 1.58 (95 % CI 1.36-1.83) for major bleeding and 1.30 (95 % CI 1.20-1.41) for any bleeding. Dabigatran was also associated with a higher HR for five types of bleeding events: 1.85 (95 % CI 1.64-2.07) for GIB; 1.41 (95 % CI 1.21-1.64) for hematuria; 2.27 (95 % CI 1.32-3.90) for vaginal bleeding; 2.78 (95 % CI 1.32-5.86) for hemarthrosis; and 1.49 (95 % CI 1.04-2.14) for hemoptysis. However, dabigatran's HR for ICH was 0.32 (95 % CI 0.20-0.50). After adjusting for patient characteristics, dabigatran was consistently associated with an increased risk of major bleeding, any bleeding event, and GIB in all subgroups.
Conclusion: After adjusting for clinical and demographic characteristics, dabigatran (compared to warfarin) was associated with a higher incidence of major bleeding and GIB, but a lower incidence of ICH.
Critique: The study used claims data and patients were followed for only 14 months. There was no assessment of the patients' incidences of stroke; thus, no conclusions regarding bleeding risks compared to stroke prevention can be made. There was no distinction in dabigatran dosing so it is unclear if the higher rates of bleeding were dose related. External validity was compromised by the subjects' ages, antiplatelet use, and CHADS2 scores. Lastly, the subjects' renal function was unknown. However, post-marketing data on real-world use of dabigatran is presented, with risks and benefits highlighted.
Implication for Toxicologists: This paper further characterizes the risk dabigatran poses to high risk patients. With this information, toxiologists should continue to advocate for the careful selection of anticoagulant in patients with AF and alert colleagues to the bleeding risk dabigatran specifically poses, especially for older patients with multiple co-morbidities, African Americans, and CKD patients. Background: The routine use of gastric decontamination (GD) in the poisoned patient has fallen out of favor in the last 20 years due, in most part, to the lack of proven benefit. However, GD is sometimes used in circumstances where time of ingestion is recent, antidotal therapy is limited and significant morbidity is expected. The Btime-since-ingestionî n which these therapies may be of benefit is still controversial.
Research Question: What are the characteristics of residual gastric contents seen on upper gastrointestinal endoscopy (UGE) in patients with oral drug overdoses?
Methods: This was a prospective observational study over a 2-year period. All patients presenting to one institution in Japan, following an oral drug overdose, underwent UGE. All subjects provided informed consent. Subjects were excluded if gastric lavage had already been performed, time-since-ingestion was unknown, number of drugs ingested was unknown, or a liquid medication was ingested. Endoscopic findings were divided into three groups based on the composition of drug in the stomach contents: tablet/food phase, soluble/fluid phase, and reticular/empty phase. The amount of drug in the stomach was also recorded.
Results: Of the 303 patients seen for drug overdose, 167 were enrolled in the study and underwent UGE. Endoscopy revealed 73 (43.7 %) subjects with gastric contents in the tablet/food phase: 50 (29.9 %) with contents in the soluble/ fluid phase and 44 (26.3 %) with contents in the reticular/ empty phase. In the subgroup that presented between 1 and 2 hours after ingestion, 56 % (27/48) had gastric contents in the tablet/food phase. Of those presenting between 2 and 4 hours after ingestion, 45 % (19/42) had gastric contents in the tablet/food phase. And among those presenting more than 4 hours after ingestion, 31 % (15/47) had contents in the tablet/food phase.
Conclusion: The residual gastric contents of patients with oral drug overdoses prior to GD were variable. There appears to be a subset of patients with prolonged presence of gastric contents in a tablet/food phase several hours after oral drug overdose. The efficacy of GD following overdose, regardless of time-since-ingestion cannot be estimated.
Critique: The major flaws with this paper include the use of self-reported historical data such as time-since-ingestion and amount of drug ingested. Additionally, there is no mention of type of medication ingested, timing of last meal, or analysis on substances removed from the stomach. All of these would have been valuable in the interpretation of the data.
Implication for Toxicologists: The authors describe the protracted appearance of tablets/food in stomach contents following oral drug overdoses. In the bedside decision of whether to perform GD following an acute oral overdose, this data may argue against the use of specific time-since-ingestion cutoffs for potential therapies.
